TRC

What you measure depends on what you separate.

📊In LC–UV potency assays, chromatographic selectivity underpins quantitative accuracy. Without adequate separation, co-eluting impurities, degradants or excipients can contribute to the measured response, introducing systematic bias into the reported potency.

💡Our latest application note explores practical strategies for building chromatographic selectivity and improving confidence in reported potency measurements.

⬇️Download the application note: https://ow.ly/S4nf50ZT3XZ

Since nitrosamine impurities were first identified in medicines, the pharmaceutical industry has relied on highly conservative approaches to protect patient safety. While appropriate, this has also resulted in extensive testing and significant resource demands.

During our recent panel discussion (▶️Watch on demand: https://ow.ly/PKoy50ZPKSN ),
toxicologist George Johnson suggested that 50–90% of today's nitrosamine testing could eventually become unnecessary if emerging scientific approaches are adopted by regulators.

📝 A recent study led by scientists at Eli Lilly and Company helps explain why. It proposes a complementary pathway in which quantitative in vivo mutagenicity data (TGR) could support the derivation of compound-specific acceptable intake limits, moving risk assessment towards a more evidence-based approach. Read the study at https://ow.ly/zYiA50ZPKSM

🎉It’s been a year since the grand opening of our Organic Chemistry Synthesis Centre of Excellence in Toronto!

That makes it the perfect time to ask our site leaders about how the new facility is helping them, their colleagues, and TRC’s ability to better serve its customers worldwide.

Q: Looking back on the past year, what achievement or milestone are you most proud of?
A: Jose Rodezno, Senior Director, Operations and Synthetic Chemistry

🙌“I’m particularly proud of introducing the Electronic Laboratory Notebook (ELN) system. That really was a milestone achievement.

Getting there required strong collaboration across our teams – to modernise our processes, improve data integrity and traceability, and create a more efficient way of working.

The new system represents a significant step forward in our digital transformation journey – one that will deliver long-term benefits for our employees, customers, and the environment.”

Q: What has impressed you most about the people and culture at the new site?
A: Damian Chung, Director, End to End Supply Chain

👩🏽‍🔬“Our people, and their ability to engage collectively as a team.

The team showed incredible adaptability and collaboration, doing whatever was needed to make this a successful and safe move.

Then, once we were in the new facility, they also impressed me with how quickly they adapted to their new spaces and new processes – making it a seamless transition.”

Q: What are you most excited about for the future of the Toronto site and its continued growth?
A: Rathika Jayasinghe, HR Director Toronto

💡“The tremendous opportunity that this new facility creates to accelerate growth, innovation, and collaboration.

Being together in a single, integrated, and world class environment has helped create stronger connections between people, ideas, and processes - enabling faster problem-solving, greater knowledge sharing, and increased operational efficiency.

Looking ahead, I see significant opportunities to enhance process excellence, drive continuous improvement, and further expand our capabilities in organic synthesis.

And all of this will enable our site to support new customer opportunities, accelerate product development, and continue growing as a strategic hub within the organisation.”

📚 Spotlight
Why do some populations experience a higher risk of to***co-related cancer despite similar smoking behaviours?

Researchers have explored this question for decades.

📝A new study led by US scientists investigates whether inherited differences in to***co carcinogen metabolism could be part of the explanation. DOI: 10.1007/s00204-026-04505-w

Focusing on NNK, a major to***co-specific nitrosamine carcinogen, the authors found that smokers with higher African genetic ancestry were more likely to exhibit a poor metaboliser phenotype. They also identified ancestry-associated genetic variants involved in to***co carcinogen metabolism and detoxification.

The findings suggest that people smoking the same number of ci******es may not receive the same biological dose of carcinogen exposure, potentially contributing to differences in to***co-related cancer risk.

✨It's a fascinating example of how biomarkers, molecular toxicology and genetics are helping us better understand individual susceptibility to carcinogens—and could ultimately support more personalised approaches to cancer prevention.

This study was supported by to***co nitrosamine research chemicals from TRC. 🔬Find out more: https://ow.ly/GE5m50ZPIV2

💊Extractables and leachables remain a critical consideration in pharmaceutical development, packaging selection, and lifecycle management.

👇Our latest flyer explores the evolving ICH Q3E framework and highlights reference standards that can support analytical testing, toxicological assessment and regulatory readiness.

⬇️Download it to discover more: https://ow.ly/EBgb50ZPOrw

LGC Extractables & Leachables Flyer

💊GLP-1 agonist-based therapies have taken the world by storm in 2026.
As weight loss treatments, they're already achieving remarkable sales in developed countries - while new dosage forms are expected to accelerate demand all around the world.

👩‍🔬Even more exciting, GLP-1s are showing promise for tackling a wide range of other ailments - including cancer, addiction, Alzheimer's, heart attacks, strokes, kidney disease, and more.

👇Our focused selection of GLP-1 research compounds is now available to support your method development, assay optimisation, and reference testing needs. It features:

✅semaglutide,
✅liraglutide,
✅exenatide acetate,
✅exenatide d5 acetate,
✅lixisenatide acetate, and
✅tirzepatide.

⬇️Explore the range: https://ow.ly/39Xo50ZGs2J